Open AccessAn Integrated Analysis of Liver Safety Data from Orlistat Clinical Trials
Author(s) -
Marc Morris,
P. W. Lane,
Kwan Lee,
Daniel J. Parks
Publication year - 2012
Publication title -
obesity facts
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.398
H-Index - 45
eISSN - 1662-4033
pISSN - 1662-4025
DOI - 10.1159/000341589
Subject(s) - orlistat , medicine , placebo , adverse effect , liver injury , odds ratio , adverse event reporting system , liver function , gastroenterology , obesity , weight loss , pathology , alternative medicine
Orlistat is an oral gastrointestinal lipase inhibitor and is indicated for treatment of obesity in combination with a hypocaloric diet. Post-marketing reports of adverse reactions revealed hints for possible drug-induced liver injury which has prompted changes to the product information. Orlistat's development program, involving over 30,000 patients, did not indicate a hepatic safety issue.